MAGE-A3/12 TCR-gene engineered lymphocytes

· National Cancer Institute (NCI)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MAGE-A3/12 TCR-gene engineered lymphocytes, covering 2013-03-27 to 2013-03-27. Get the full timeline:

Most recent: Clinical Trial Update: MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes [Phase 1, Phase 2]